Schrödinger (SDGR) is back in focus after first quarter 2026 results combined a reported earnings miss with 12% growth in Annual Contract Value, along with fresh attention on its upcoming Bunsen AI co-scientist launch.

Recent trading reflects this renewed interest, with a 1 month share price return of 16.59% and 7 day share price return of 11.04%. However, the year to date share price return of negative 26.14% and 1 year total shareholder return of negative 44.39% show momentum rebuilding from a weaker longer term base.

If Schrödinger’s AI push has caught your attention, it could be a good moment to broaden your research and check out 35 healthcare AI stocks

With the stock down sharply over 1 year but rallying in recent weeks, and trading at a sizeable discount to the average analyst price target, the key question is whether this represents a reset entry point or if future growth is already fully reflected in the current valuation.

Most Popular Narrative: 37.9% Undervalued

At a last close of $13.28 versus a narrative fair value of $21.38, the current price sits well below what this widely followed model implies.

Strong pipeline advancement and early clinical success, such as positive Phase I data for SGR-1505, positions the company to secure additional milestone payments, royalties, and out-licensing deals, creating potential for substantial long-term revenue growth and more predictable future cash flows.

Want to see what sits behind that confidence in future cash flows? The narrative leans on steady revenue expansion, margin repair, and a premium future earnings multiple. Curious how those elements combine into a single fair value number?

Result: Fair Value of $21.38 (UNDERVALUED)

However, the narrative can unravel if software growth stays concentrated in existing customers while hosted delivery continues to pressure margins and makes reported revenues more volatile.

Another Way To Look At Value

The earlier fair value comes from a narrative style model, but the current P/S of 3.9x tells a different story. That is far above the US Healthcare Services industry at 2.2x, the peer average at 1.6x, and the fair ratio of 1.9x, which points to meaningful valuation risk if sentiment cools.

To understand what this pricing gap might mean for your own expectations, it helps to see how the underlying numbers stack up against peers, the wider industry, and where the fair ratio suggests the market could eventually settle. You can then decide which signal you trust more.

Next Steps

The mix of cautious and optimistic signals in this article might leave you undecided. Consider taking a closer look while the stock is in focus and weigh the full picture for yourself with 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Schrödinger has sparked your curiosity, do not stop here. Broaden your watchlist with focused stock ideas that match different risk and return preferences.

• Target potential upside by reviewing companies that screen as 51 high quality undervalued stocks before they move back toward what the market considers fair.
• Strengthen your income stream by scanning for stocks that appear as 12 dividend fortresses and see which payouts look better supported by current fundamentals.
• Prioritise resilience by checking out 72 resilient stocks with low risk scores that may suit a steadier, sleep at night segment of your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.